In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species

The in vitro susceptibilities of 170 clinical isolates plus 12 American Type Culture Collection strains of Pasteurella species comprising nine species and three Pasteurella multocida subspecies were studied by an agar dilution method. Garenoxacin (BMS-284756), a new des-fluoro(6) quinolone, was active at less than or equal to0.06 mug/ml against all isolates, including four beta-lactamase-producing strains, with >90% of the strains susceptible to less than or equal to0.008 mug/ml. Garenoxacin was generally 1 to 2 dilutions more active than levofloxacin and moxifloxacin and was the most active agent tested. Cefoxitin required 1 mug/ml for inhibition of 51 of 182 (29%) of strains, and 3 strains (also beta-lactamase producers) were resistant to doxycycline.